Qiagen NV

QIA

Equity

ISIN NL0015001WM6 / Valor 132350663

Xetra (2024-09-18)

EUR 41.19-0.95%

Qiagen NV
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Qiagen NV is a leading provider of molecular testing solutions in the fields of molecular diagnostics and life sciences. The company offers a wide range of products and services that support customers in various stages of molecular testing, from sample extraction to data analysis. Qiagen's portfolio includes testing technologies for single or multiple molecular variants, as well as automation systems that streamline the testing process. With a focus on delivering valuable insights to customers, Qiagen plays a crucial role in advancing research and improving patient outcomes in the healthcare industry.

Summarized from source with an LLMView SourceSector: Technology

Net Sales

In Q3 2023, Qiagen NV reported net sales of $476 million, which represents a 5% decline at actual rates and a 6% decline at constant exchange rates (CER) compared to the same period in 2022. However, net sales at CER of $470 million exceeded the company's outlook of at least $465 million CER.

Adjusted Earnings Per Share

Qiagen NV's adjusted diluted earnings per share (EPS) for Q3 2023 were $0.50, surpassing the company's outlook of at least $0.48 CER. This performance highlights the company's ability to manage costs effectively and maintain profitability despite a challenging macroeconomic environment.

Non-COVID Product Growth

Sales of non-COVID products grew by 5% CER in Q3 2023, reaching $442 million. This growth was driven by higher sales from instruments as well as recurring consumables and related revenues, indicating strong underlying demand for Qiagen NV's core product portfolio.

Full-Year 2023 Outlook

Qiagen NV has reaffirmed its full-year 2023 outlook, projecting net sales of at least $1.97 billion CER and adjusted diluted EPS of at least $2.07 CER. This outlook is supported by solid demand for consumables, which accounted for 88% of total sales in the first nine months of 2023.

Geographic Sales Performance

In Q3 2023, Qiagen NV's sales in the Americas grew by 1% CER, driven by higher sales in the U.S. and strong performance of the QuantiFERON-TB test. However, sales in Europe, the Middle East, and Africa declined by 11% CER, and sales in the Asia-Pacific/Japan region fell by 16% CER, reflecting regional market challenges.

Summarized from source with an LLMView Source

Key figures

4.98%1Y

%3Y

%5Y

Performance

20.7%1Y

19.2%3Y

19.2%5Y

Volatility